The I-SPY2 Trial is transforming breast cancer treatment, offering new insights into pre-surgery chemotherapy for invasive lobular breast cancer (ILC). Presented at the 2025 American Society of Breast Surgeons (ASBrS) meeting, this study explores surgical outcomes and lymph node response in high-risk tumors. In an exclusive interview, Rita Mukhtar, MD, a breast surgeon at UCSF, … Continue reading 2025 Breast Cancer Treatment: I-SPY2 Trial’s Lobular Chemotherapy Breakthrough